| View Larger Image | Science Business: The Promise, the Reality, and the Future of Biotech | Hardcoverby Gary P. Pisano (Author)
| List Price: | $29.95 | | Price: | $20.42 | | You Save: | $9.53 (32%) | | | Available: | Usually ships in 24 hours |
| | Binding: | Hardcover | | Publisher: | Harvard Business Press | | Edition: | 1st Edition | | Page Count: | 237 Pages | | Publication Date: | November 14, 2006 | | Sales Rank: | 245,879th |
|
FEATURES | - ISBN13: 9781591398400
- Condition: NEW
- Notes: Brand New from Publisher. No Remainder Mark.
- Click here to view our Condition Guide and Shipping Prices
|
EDITORIAL REVIEWS |
Product Description
Why has the biotechnology industry failed to perform up to expectations—despite all its promise? In Science Business, Gary P. Pisano answers this question by providing an incisive critique of the industry. Pisano not only reveals the underlying causes of biotech’s problems; he offers the most sophisticated analysis yet on how the industry works. And he provides clear prescriptions for companies, investors, and policymakers seeking ways to improve the industry’s performance. According to Pisano, the biotech industry’s problems stem from its special character as a science-based business. This character poses three unique business challenges: 1) how to finance highly risky investments under profound uncertainty and long time horizons for R&D, 2) how to learn rapidly enough to keep pace with advances in drug science knowledge, and 3) how to integrate capabilities across a broad spectrum of scientific and technological knowledge bases. The key to fixing the industry? Business models, organizational structures, and financing arrangements that place greater emphasis on integration and long-term learning over shorter-term "monetization" of intellectual property. Pisano maintains that all industry players—biotech firms, investors, universities, pharmaceutical companies, government regulators—can play a role in righting the industry. The payoff? Valuable improvements in health care, and a shinier future for human well-being. |
CUSTOMER REVIEWS (Average Customer Rating: 4.0 based on 10 reviews)
|
Science Business by S. Hwang  1 Stars
February 13, 2009
I haven't got this product.
I've also sent an email to the seller, but s/he haven't response it yet.
I would like to refund it.
| |
stale and insular by kerrjac  2 Stars
January 25, 2009
This book begins with the insight that good science is different from good business. Beyond this, I found the rest of the book kind of stale.
The author extensively discusses the idiosyncrasies of the biotech industry. He talks about the great amount of capital and trail-and-error required in drug development, supposedly with the intention of arguing that biotech is different from other sectors. However, I kept thinking, "But of course biotech is different from other sectors, it's a different sector." What this book lacked, I thought, were more comparisons and similarities between other areas of business. While biotech is the only industry that actively seeks drugs that hit molecular targets, it's not the only industry that heavily progresses through research and development. I was surprised that the author didn't tap the extensive history of R&D in other private sectors. After all, there's an array of specific examples to choose from, be it the microprocessor chip wars or the development of hybrid cars. Using lessons from those endeavors, and connecting them to biotech, I thought, could've been pretty novel.
Instead, the author rarely pulls insights from outside of the biotech industry, while maintaining that biotech is new, not fully developed, and can learn a lot from business. As such, the book has a very insular feel and seems very limited in scope.
| |
A solid introduction to Biotech from a business perspective by Mike Sweeny (California)  5 Stars
July 26, 2007
I found this book to be well-researched, current, and insightful. If you're at all interested in the biotech business, especially in starting a company or investing, read this book first. Pisano's narrative really helps one understand the foundations of the biotech industry, and sheds some light on what does, and doesn't, work within that industry. The fact that it's off the Harvard Business School Press gives it additional credibility, which is well deserved. A wealth of references, as well as a listing of the companies listed in the study, give the reader both a sense of the research that went into the book and a start on the search for more resources on the subject.
| |
Extrememly lucid, well thought out analysis by Jeff (Northern California) 5 Stars
May 17, 2007
For my money, most business school professors write with a detached, dry atmosphere about business topics.
Not Gary Pisano!
He has a strong point of view that the ecosystem for biotech is not working well. His observations about why are right to the point and convincing.
His prescriptions are well worth considering.
If you're new to biotech, this is a great book to start out with. I would then proceed to Building Biotechnology, which is also a fine book.
| |
Not what I expected by Seth Maier (San Jose, CA USA) 1 Stars
May 02, 2007
I don't know what I expected from this book, except for some new insights on how to invest in the biotech industry. I was extremely disappointed to find a whiney critique of biotech companies that take enormous risks in discovering new life-saving or life-improving chemicals, and oftentimes crash and burn in the process. Well, that's capitalism, for ya'! Would the author prefer a centrally run system in which lazy bureaucrats barely advance scientific discovery? It all comes back to risk and reward. This book is the updated version of complaints about Silicon Valley, and the dot-com bust. OK, the technology business may not be profitable as a whole, but the efforts of millions of people in the pursuit of the big payoff has created great advances and has improved lives in making people more efficient, more educated, and less carbon-intensive.
| |
SIMILAR PRODUCTS |
| From Alchemy to IPO: The Business of Biotechnology
by Cynthia Robbins-roth (Author)
A fascinating glimpse inside the life-and-death business of biotechnology. "A tour-de-force for anyone who is interested in the biotech industry. I applaud the enormous achievement of Cynthia Robbins-Roth." -Frederick Frank, Senior Managing Director & Vice Chair, Lehman Brothers "From Alchemy to IPO tells the dramatic story of this revolutionary industry as only an insider can." -George Rathmann, President and CEO, ICOS Corporation, Chairman Emeritus, Amgen Written by a well-known...
| 
| Science Lessons: What the Business of Biotech Taught Me About Management
by Gordon Binder (Author), Philip Bashe (Author)
Widely regarded as the most innovative, successful biotech firm ever, Amgen led its industry in revenue and sales growth in 2007. Top magazines including Fortune and Industry Week have repeatedly named it one of America's best companies to work for.
In Science Lessons, Gordon Binder--CEO and chairman during 1988-2000--describes Amgen's climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just...
| 
| The Business of Healthcare Innovation
by Lawton Robert Burns (Editor)
Robert Lawton Burns focuses on the key role of the 'producers' as the main source of innovation in this wide-ranging analysis of business trends in the manufacturing branch of the health care industry. Written by industry academics and executives, the book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. Most importantly, it describes the growing convergence between these sectors and the need for...
| 
| The Billion Dollar Molecule: One Company's Quest for the Perfect Drug
by Barry Werth (Author)
Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing -- atom by atom -- both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS. You will be hooked from start to...
| 
| Drugs: From Discovery to Approval
by Rick Ng (Author)
“Concise and easy to read, the book quickly introduces basic concepts, then moves on to discuss target selection and the drug discovery process for both small and large molecular drugs.” –Doody's Reviews, May 2009 "The second edition of a book that offers a user-friendly step-by-step introduction to all the key processes involved in bringing a drug to the market, including the performance of preclinical trials." –Chemistry World, February 2009
The new edition of...
|
|
|
